0.432
0.00 (0.00%)
| Previous Close | 0.432 |
| Volume | 84,360 |
| Price / Earnings (Forward) | 42.73 |
| Price / Sales | 0.470 |
| Price / Book | 1.43 |
| 52 Weeks Range |
| Profit Margin | -122.63% |
| Operating Margin (TTM) | -71.54% |
| Diluted EPS (TTM) | -0.260 |
| Quarterly Revenue Growth (YOY) | 857.20% |
| Total Debt/Equity (MRQ) | 45.07% |
| Current Ratio (MRQ) | 0.640 |
| Operating Cash Flow (TTM) | -33.17 M |
| Levered Free Cash Flow (TTM) | 50.39 M |
| Return on Assets (TTM) | -28.90% |
| Return on Equity (TTM) | -114.74% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Vaxart, Inc. | Mixed | Mixed |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 1.5 |
| Technical Oscillators | -2.5 |
| Average | -1.57 |
|
Vaxart Inc is a clinical-stage biotechnology company. It focuses on the development of oral recombinant vaccines based on its Vector Adjuvant Antigen Standardized Technology to protect against a wide range of infectious diseases. The products under its tablet pipeline consist of the treatment of Coronavirus, Norovirus, Seasonal Influenza, RSV(respiratory syncytial virus), and HPV(Human papillomavirus) Therapeutic. It operates in a single segment, which is the discovery and development of oral recombinant protein vaccines. Geographically all the business activity functions through the region of the United States. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 0.88% |
| % Held by Institutions | 12.08% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Beacon Capital Management, Llc | 31 Dec 2025 | 0 |
| Custos Family Office, Llc | 31 Dec 2025 | 0 |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |